.jpg)
STAT+: Altimmune to study obesity drug in alcohol use disorder, following Eli Lilly
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Morning. The Boston biotech scene's a mess, and Marty…
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Morning. The Boston biotech scene’s a mess, and Marty Makary’s and Jay Bhattacharya’s nominations have been advanced to the full Senate for FDA and NIH leadership. Also, we see another company testing GLP-1s for alcohol use disorder.
Boston area’s biotech slump is raising concerns
The Boston area biotech sector was for a while bullish that perhaps 2025 was the year everything would turn back around after a prolonged slump. Instead, it finds itself mired in uncertainty thanks to falling stock valuations, layoffs, and far too much open lab space.
